Conception soon after discontinuing interferon/ribavirin therapy: A successful outcome [19]

American Journal of Gastroenterology

Volumn 96, Issue 7, 2001, Pages 2285-2286

  Mishkin, Daniel ^a   Deschênes, Marc ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; CASE REPORT; CHRONIC HEPATITIS; COMBINATION CHEMOTHERAPY; CONCEPTION; DRUG SAFETY; FEMALE; HUMAN; LETTER; PRIORITY JOURNAL; TERATOGENICITY; TREATMENT OUTCOME;

EID: 0034933314     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02559-X     Document Type: Letter

References (5)

1. Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
2. Two cases of CML treated with alpha interferon during second and third trimester of pregnancy with analysis of the drug in the new-born immediately postpartum
3. Congenital anomalies induced in hamster embryos with ribavirin
4. Teratogenic effects of ribavirin on hamster and rat embryos
5. Embryotoxic, teratogenic and metabolic effects of ribavirin in mice